{"id":1364,"date":"2026-03-15T03:27:01","date_gmt":"2026-03-15T03:27:01","guid":{"rendered":"https:\/\/perfusfind.com\/ic\/?p=1364"},"modified":"2026-03-15T03:27:02","modified_gmt":"2026-03-15T03:27:02","slug":"non-mechanical-haemodynamic-support-in-acute-pulmonary-thromboembolism-a-scoping-review","status":"publish","type":"post","link":"https:\/\/perfusfind.com\/ic\/index.php\/2026\/03\/15\/non-mechanical-haemodynamic-support-in-acute-pulmonary-thromboembolism-a-scoping-review\/","title":{"rendered":"Non-mechanical haemodynamic support in acute pulmonary thromboembolism: a scoping review"},"content":{"rendered":"

Abstract:<\/strong><\/p><\/blockquote>\n

This scoping review<\/strong> maps all non-mechanical haemodynamic support<\/strong> used in acute pulmonary embolism (PE)<\/strong> while definitive clot-reducing therapy is pursued. Across animal studies, case series, observational cohorts, trials, and reviews, the authors catalogue vasopressors, inotropes, fluids, and pulmonary vasodilators<\/strong>. Evidence is heterogeneous and mostly low-quality<\/strong>; some agents improve physiological surrogates (CO, PVR, RV function), but robust outcome data are sparse<\/strong>, and standardized recommendations are limited.<\/p>\n

\"\"<\/p>\n

Key Insights:<\/strong><\/p><\/blockquote>\n

    \n
  1. Scope of evidence:<\/strong> 57 agents<\/strong> identified across animal and human<\/strong> studies; human data are dominated by small, non-randomized reports.<\/li>\n
  2. Vasopressors:<\/strong> Agents like norepinephrine<\/strong> are frequently used to restore systemic pressure and RV coronary perfusion; comparative human data remain limited.<\/li>\n
  3. Inotropes:<\/strong> Dobutamine<\/strong> and phosphodiesterase-3 inhibitors (e.g., milrinone)<\/strong> can augment RV contractility but may precipitate hypotension without concurrent vasopressor support.<\/li>\n
  4. Pulmonary vasodilators:<\/strong> Inhaled nitric oxide<\/strong> and prostacyclin analogues (e.g., epoprostenol\/iloprost)<\/strong> reduce RV afterload and improve short-term haemodynamics; clear survival benefit is unproven<\/strong>.<\/li>\n
  5. Fluids:<\/strong> Excess preload can worsen RV dilation and septal shift; the mapped literature supports cautious, small-volume fluid strategies<\/strong> rather than aggressive boluses in shock unless hypovolaemia is evident.<\/li>\n<\/ol>\n

    Why This Matters:<\/strong><\/p><\/blockquote>\n

    Right-ventricular failure drives early mortality in acute PE. This review clarifies what we <\/strong>think<\/em><\/strong> helps (pressors, selective inotropes, inhaled vasodilators, cautious fluids)<\/strong> versus what we <\/strong>know<\/em><\/strong>\u2014highlighting the evidence gaps<\/strong> that should shape protocols and trials.<\/p>\n

    Conclusion:<\/strong><\/p><\/blockquote>\n

    Non-mechanical haemodynamic support in acute PE is biologically plausible and physiologically helpful<\/strong> in small studies, but high-quality outcome evidence is lacking<\/strong>. Practice should prioritize norepinephrine-anchored MAP support<\/strong>, selective inotropy when low output is present<\/strong>, inhaled vasodilators for RV afterload<\/strong>, and judicious fluids<\/strong>, while the field pursues prospective, adequately powered trials<\/strong>.<\/p>\n

    Take-Home for Clinicians:<\/strong><\/p><\/blockquote>\n